GLP-1 Insurance Coverage and Access Guide

Begin with the drug and indication

GLP-1 coverage is product-specific. Wegovy is a semaglutide product with approved weight-management uses. Zepbound is a tirzepatide product with approved weight-management uses. Ozempic and Mounjaro use related active ingredients, but their approved indications and labels are not interchangeable with the weight-management brands. A benefits representative may need the product name, diagnosis, and prescriber documentation before giving a reliable answer.

This distinction also protects against an expensive mistake. A website that says a plan covers semaglutide has not established that it covers every semaglutide product, every indication, or every pharmacy channel. Ask about the exact National Drug Code or prescribed presentation when the plan requires that level of detail.

Use a six-question coverage call

Ask whether the exact drug is on the current formulary, whether the prescribed indication is covered, what prior authorization requires, whether step therapy applies, which pharmacies are in network, and what the estimated patient responsibility is after the deductible. Record the date, representative, reference number, and the documents requested.

A useful answer separates a deductible, copay, coinsurance, and noncovered cash price. It also says whether approval is temporary and what renewal evidence may be needed. If the answer is no, ask for the written denial reason and the plan's appeal process. Those details determine the next move far better than a generic statement that GLP-1 drugs are covered or excluded.

Medicare access changed in 2026

CMS launched the Medicare GLP-1 Bridge on July 1, 2026. The short-term demonstration runs through December 31, 2027 and provides certain eligible Part D beneficiaries access to eligible GLP-1 drugs through a central claims pathway. CMS states that eligible beneficiaries pay a $50 copay and that the demonstration operates outside the ordinary Part D benefit payment flow.

The $50 does not apply to the Part D deductible, does not count toward true out-of-pocket costs, and cannot be reduced with a coupon or routine discount program. The current CMS product list includes all Foundayo formulations, all Wegovy formulations, and Zepbound KwikPen. Zepbound single-dose vials and single-dose pens are not currently included. CMS says this list can change.

The Bridge is not a blanket promise that every Medicare beneficiary or every GLP-1 product qualifies. A prescriber must submit prior authorization for weight management and attest to current lifestyle modification plus one of CMS's specified BMI and comorbidity pathways. Prescriptions for Part D-coverable uses such as type 2 diabetes, moderate to severe obstructive sleep apnea, or qualifying MASH should continue through the beneficiary's Part D plan rather than the Bridge.

Savings cards and direct cash programs solve different problems

Manufacturer savings programs can reduce costs for some commercially insured or cash-paying patients, but the current terms define who qualifies, which prescription is eligible, how long the offer lasts, and the maximum benefit. They are not insurance and may exclude people enrolled in federal or state health programs. Read the current terms on the day of purchase because eligibility and benefit amounts can change.

A direct cash pathway can be simpler, but it still needs a complete total. Confirm whether the figure includes the branded medication, clinician visit, membership, laboratory work, supplies, shipping, and follow-up. A low membership price with medication billed separately is not comparable to an all-in medication program.

Compounded GLP-1 access has a separate legal and safety boundary

Compounded semaglutide and tirzepatide products are not FDA-approved drug products and should not be described as generic Wegovy, Ozempic, Zepbound, or Mounjaro. FDA says compounded drugs should be used only when a patient's medical need cannot be met by an approved drug. The agency also describes dosing errors, fraudulent labels, salt-form concerns, and adverse-event reports associated with unapproved GLP-1 products.

FDA's April 2026 clarification says semaglutide and tirzepatide are not currently on the drug-shortage list and explains restrictions on routinely making products that are essentially copies of commercially available approved drugs. A telehealth listing therefore needs a current pharmacy, prescription, product, and legal basis. A cheap checkout is not evidence that those questions have been answered.

Do not substitute a compounded or differently branded product for the prescribed product without the prescribing clinician and dispensing pharmacy resolving the clinical and legal questions.

Compare the final access pathway

The best pathway is the one that remains clinically appropriate after the coverage facts are known. For one person that may be a covered branded prescription after prior authorization. For another it may be a manufacturer cash option, an appeal, a different covered medicine, or a nonmedication program. The ranked catalog below compares current commercial terms; it does not establish coverage or eligibility.

Before paying, save the approval or denial, checkout total, renewal schedule, cancellation rule, medication name, pharmacy name, and verification date. That record makes later billing problems easier to resolve and keeps a promotional headline from replacing the actual agreement.